Q&A

The synergy between the cutting-edge features of the MCT Kit^® and the versatile functionality of the MCT Unit^® forms the foundation of a revolutionary innovation conceived to elevate the regenerative potential of PRP and cell-based therapies, while stimulating the production and deliverance of autologous exosomes.

The MCT Unit^® emits light across a versatile wavelength spectrum (467 nm to 850 nm): blue light (467 nm), green light (530 nm), yellow light (591 nm), red light (620 nm), and infrared light (850 nm). Additionally, it is equipped to stimulate biological materials within a temperature range of 4ºC to 45ºC.

The MCT Kit^® is a patented medical-grade cassette serving as the receptacle for patient material, uniquely crafted to fit in the MCT Unit^®. It has two syringe docking sites (standard and Luer Lock^® compatible) to insert and extract autologous material.

Direct exposure of cells to light profoundly affects chromophores, including cytochrome C oxidase and opsins. These light-responsive receptors activate second messengers (ROS, Ca²⁺, ATP, cAMP, NO), modulating cell signaling pathways.

It is well known that low temperatures (4ºC) prime platelet activation and trigger the release of growth factors (VEGF, EGF, and bFGF) from α-granules. Additionally, temperature directly influences exosome secretion kinetics, with increased exosome release at higher temperatures (37ºC).

All autologous materials can be enhanced with the MCT System. That is, basically, PRP, SVF, and every other regenerative medicine preparate. Therapy enhancement translates, for instance, into considerably fewer sessions and stunning clinical results. Safe, effective, evidence-proof photothermal boosting treatments are here to stay.

There is a “flash” effect that can be seen almost immediately and an antiaging effect whose results can be seen in less than a month but can be enhanced with time due to the regenerative power of exosomes.

PRP preset is recommended for plasma-derived products, such as PRP (platelet-rich plasma) or PPP (platelet-poor plasma). Cells preset is versatile and can be employed for various cell types, including serum, biopsies, stromal vascular fraction, stem cells, as well as other cell types. Exosomes preset is suitable for any biologic liquid containing living cells or platelets.

For MCT Technology to exert its therapeutic effects, autologous material must be liquid and contain living cells or platelets.

The MCT protocol involves 3 key steps. First, procuring the autologous material from the patient. Second, inserting the patient’s material into the MCT Kit^®. Third, setting up the MCT Unit^® with the loaded MCT Kit^®, running the preferred MCT preset, extracting the MCT material once the session is over, and administering it to the patient.

Yes. There are 3 different MCT presets (PRP, Cells, and Exosomes presets) which can be used individually. However, for a superior outcome we strongly recommend splitting the patient material and combining PRP or Cells presets with Exosomes preset.

A combined MCT treatment merges PRP or Cells presets with the Exosomes preset for enhanced therapeutic results. Patient’s material is split in two halves of equal volume. The first half is used for either PRP or Cells presets to obtain MCT Plasma or MCT Cells respectively, while the second half is used to run Exosomes preset and generate MCT Exosomes. This way the patient receives MCT Plasma or MCT Cells, as well as MCT Exosomes.

The MCT Kit^® allows a maximum of 10 mL. While 10 mL is enough for individual MCT treatments, we recommend an initial volume of 20 mL for combined MCT treatments. These 20 mL can be divided into two 10 mL halves for individual presets.

PRP or Cells presets are first run on the MCT Unit^® to obtain MCT Plasma or MCT Cells. While the patient receives MCT Plasma or MCT Cells, Exosomes preset can be started to generate MCT Exosomes. By performing these steps simultaneously, the duration of the session can be reduced up to 25-30 minutes.

We recommend scheduling treatment sessions with a 3-week interval and maintaining a span of 4-6 months between subsequent maintenance sessions. While this timeline serves as a general guideline, it is essential to tailor it to the specific needs of each individual patient if necessary.

Exosomes originating from keratinocytes, fibroblasts, stem cells, and diverse skin cells play a pivotal role in a range of critical functions, spanning from the self-renewal of the epidermis to skin regeneration, hair follicle stem cell proliferation and differentiation, and the modulation of immunological processes crucial for skin homeostasis.

Exosomes, with their unique ability to transfer biological information and promote tissue repair, emerge as a promising strategy for addressing diverse skin disorders. From wound healing to pigmentation regulation, skin rejuvenation, hair loss recovery, and scar remodeling, exosomes hold promise in diverse therapeutic applications.

The main distinctive factor among autologous, allogeneic, and xenogeneic exosomes lies in their source. Autologous exosomes originate from cells of the same individual, allogeneic exosomes derive from cells of a different individual of the same species, and xenogeneic exosomes come from cells of a different species.

Autologous exosomes benefit from immune privilege, while heterologous exosomes are prone to triggering an immune response in the patient. The resulting immunogenic response contributes to the short-lived nature of heterologous exosomes, limiting their efficacy and therapeutic potential. Safety concerns also arise from the potential risk of cross- or intra-species contamination associated with the use of heterologous exosomes. All these factors position autologous exosomes as a valid medicinal therapeutic option, while heterologous exosomes are primarily confined to cosmetic applications.

Unlike conventional methods that merely isolate or concentrate exosomes in cosmetic products, our technology goes beyond; it actively stimulates the production and release of naïve autologous exosomes from cells and platelets. This unique approach sets MCT technology apart from other exosome products in the market, positioning MCT Exosomes as a secure, efficient, potent, and reliable therapeutic option.

MCT technology elevates standard PRP to MCT Plasma, enhancing growth factor release, refining platelet activation, reducing proinflammatory cytokines, optimizing pH balance, decreasing plasma density for a more comfortable injection, and stimulating platelet metabolism via ATP synthesis.

The best approach is to let them know that there is a new, enhanced regenerative product that is much stronger than standard PRP. It is a new generation top tech treatment that is called MCT Plasma and will lead them to better results in fewer sessions.